Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market

Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2024-2030: Prominent trends in global Diphtheria, Pertussis, and Tetanus (DPT) vaccine include increased vaccination coverage, introduction of combination vaccines, improved cold chain logistics, enhanced surveillance systems, and rising awareness of vaccine-preventable diseases.

Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine is valued at USD 6.1 Billion in 2023 and it is expected to generate absolute dollar opportunity of USD 7.9 Billion by 2030.

Scope of Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine

The Diphtheria, Pertussis, and Tetanus (DPT) vaccine is a crucial component of routine immunization programs worldwide. Diphtheria caused by Corynebacterium diphtheriae, it can lead to severe respiratory issues, heart failure, paralysis, and even death. Pertussis (Whooping Cough) is caused by Bordetella pertussis, it is highly contagious and can cause severe coughing fits, breathing difficulties, and complications, particularly in infants. Tetanus (Lockjaw) is caused by Clostridium tetani, it leads to muscle stiffness and spasms, which can be life-threatening without treatment. These vaccines are given either in youth or middle age to deliver the acquired immunity against Diphtheria, Pertussis, and Tetanus. Diphtheria, Tetanus, and pertussis or DPT are serious diseases brought about by the bacteria. DPT vaccine is a mix of diphtheria and tetanus pathogens adsorbed with pertussis vaccine for intramuscular vaccination. Diphtheria and tetanus pathogens and pertussis immunization are suggested at the same time for the successful vaccination of kids up to seven years old against Diphtheria, Tetanus, and Pertussis (outshining cough) gives an effective lift to the market development.

DPT vaccination is a key component of public health initiatives aimed at controlling and eliminating these diseases, particularly in low- and middle-income countries where the burden is higher. Widespread vaccination helps achieve herd immunity, protecting those who cannot be vaccinated, such as newborns and individuals with certain medical conditions.

COVID-19 Impact on the Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market

“Covid-19 had a negative impact on Diphtheria, Pertussis, and Tetanus (DPT) Vaccine due to the high risk of outbreaks”

The pandemic caused interruptions in global supply chains, affecting the production and distribution of DPT vaccines. Lockdowns, travel restrictions, and reduced manufacturing capacity contributed to these disruptions. Health systems worldwide focused resources on combating COVID-19, leading to reduced attention and resources for routine immunization programs, including DPT vaccination campaigns.

Many vaccination programs were postponed or canceled to limit the spread of COVID-19, leading to decreased immunization rates. This has resulted in gaps in immunity among children, increasing the risk of outbreaks. Restrictions on movement and fear of contracting COVID-19 led to decreased visits to healthcare facilities, further reducing vaccine uptake.

However, in response to the disruptions, various global health organizations and governments have initiated catch-up vaccination campaigns to address the immunization gaps caused by the pandemic. Organizations like the World Health Organization (WHO), Gavi, the Vaccine Alliance, and UNICEF have worked to enhance coordination and support for countries to maintain and restore immunization services.

Key Players of Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Report-

Some of the prominent players in the global diphtheria, pertussis, and tetanus (DPT) vaccine include GlaxoSmithKline plc (GSK), Sanofi Pasteur, Merck & Co., Inc., Pfizer Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech International Limited, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Panacea Biotec Ltd., Biological E. Limited, LG Chem, AJ Vaccines, Mass Biologics, Meiji Holdings Lanzhou Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Walvax Biotechnology Co., Ltd., Biological E. Limited, Pasteur Institute of India and others.

What significant has happened recently in Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine

FDA Approves Vaccine for Use During Third Trimester of Pregnancy to Prevent Whooping Cough in Infants Younger Than Two Months of Age

October 7th, 2022; the U.S. Food and Drug Administration approved Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis) Vaccine, adsorbed, for vaccination during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in newborns younger than two months. When the Boostrix vaccine is administered during pregnancy, it increases antibodies in the mother, which are then transferred to the developing baby.

Market Drivers

Rising Routine Immunization Programs Skyrocket Market of DPT Vaccines

The DPT vaccines are included in the Universal Immunization Programme for children. Immunization boosts the immune system to foster stronger immunity. Infants and young children who are immunized as directed by their doctors will develop the strongest immune systems, reducing their risk of life-threatening infections. For instance, the Universal Immunization Program (UIP) is one of the largest public health programs, targeting approximately 2.67 crore infants and 2.9 crore pregnant women each year.

According to the World Health Organization (WHO), in 2022, about 84% of infants worldwide—totaling approximately 110 million—received three doses of the diphtheria-tetanus-pertussis (DPT3) vaccine. This widespread vaccination coverage is crucial in protecting infants against infectious diseases that can cause severe illness, disability, or even death. DPT3 vaccination is a key component of global immunization efforts, aiming to provide broad protection against diphtheria, tetanus, and pertussis, thereby contributing to public health improvements worldwide.

In conclusion, the widespread adoption and administration of the DPT vaccine play a pivotal role in reducing the incidence of these serious diseases, protecting vulnerable populations, and advancing global public health goals. Continued support and expansion of immunization programs are essential for maintaining and improving these health gains.

Increasing Prevalence of Tetanus is anticipated to drive demand in the Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine

Tetanus, caused by the bacteria Clostridium tetani, is a serious disease that enters the body through wounds contaminated with soil, particularly affecting mothers during childbirth and newborns. The bacteria produce a toxin that disrupts nerve function, potentially leading to severe symptoms like muscle stiffness, spasms, and in severe cases, paralysis, difficulty breathing, and death.

As per the Word in Data Organization, despite vaccination efforts, tetanus still claims around 50,000 lives globally each year. Hence, increasing prevalence of tetanus, highlights the critical role of vaccination in preventing tetanus-related morbidity and mortality and achieving public health goals worldwide supporting the market growth of the global diphtheria, pertussis and tetanus vaccine market.

Market Restraints

Side Effects Associated with DPT Vaccine Hampering the Market Growth

The side effects associated with the DPT (Diphtheria, Tetanus, Pertussis) vaccine have impacted its market growth. While the DPT vaccine is crucial for preventing life-threatening diseases, concerns about its side effects have led to hesitancy among some parents and healthcare providers.

According to the CDC, common side effects of the DTaP vaccine, which is administered to children, include local reactions at the injection site, fever, irritability, and loss of appetite. More severe side effects, though rare, can include high fever, seizures, and continuous crying for over three hours. Despite these concerns, the vaccine is generally considered safe, with severe side effects being extremely uncommon.

The Vaccine Adverse Event Reporting System (VAERS), established by the U.S. Department of Health and Human Services, collects data on adverse events following vaccinations. While it is a passive surveillance system and may underreport certain events, the data indicates that severe reactions are infrequent and typically not fatal. However, the presence of these reports has contributed to vaccine hesitancy, impacting market growth.

Efforts to mitigate these concerns include public education campaigns emphasizing the vaccine's safety and the risks of not vaccinating. The CDC continues to recommend DPT vaccines, highlighting their role in preventing diphtheria, tetanus, and pertussis, which can cause severe health complications or death in unvaccinated children.

In conclusion, while side effects from DPT vaccines exist, they are typically mild and temporary. Addressing public concerns through education and transparent reporting is essential to maintain and grow the vaccine market while ensuring public health safety.

High Costs Associated with DPT Vaccines Restraining Market Growth

Developing vaccines involves extensive research, clinical trials, and regulatory approval processes, which require substantial financial investment. The costs include funding for research institutions, clinical trials, and regulatory submissions. Vaccine production requires specialized facilities, equipment, and skilled labor. Vaccines priced at higher rates are unaffordable for individuals in low-income regions or underfunded healthcare systems. This limits accessibility and reduces vaccination rates, especially for diseases like Diphtheria, Pertussis, and Tetanus (DPT) where widespread coverage is critical for effective prevention. For instance, as of June 7, 2024, the CDC Vaccine Price List indicates that DTaP vaccine available in a 10-pack of single-dose vials, is priced at US$21.688 per dose.

Thus, the high cost for the production of vaccines hamper the market expansion as well as decrease the sale in low and middle income countries.

Market Opportunities

Research and Development: Continued investment in research and development for new DPT vaccine formulations, including improved efficacy, reduced side effects, and broader protection, opens avenues for product innovation and differentiation in the market.

For instance, in December 2022, Pharmaniaga LifeScience Sdn Bhd (PLS), has entered into a research collaboration agreement with BioNet-Asia Co., Ltd (BioNet) for the development of a 6-in-1 Hexavalent Vaccine. The vaccine will provide the best possible immune response of the hexavalent vaccine against six diseases, diphtheria (DT), tetanus (TT), pertussis (aP), poliomyelitis (IPV), Haemophilus influenzae type b (Hib), and hepatitis B (Hep-B).

Expanded Immunization Programs: Increasing emphasis on routine immunization programs in developing countries and emerging markets presents a significant opportunity for expanding DPT vaccine coverage. Efforts by governments and international organizations to strengthen healthcare infrastructure and improve vaccination rates contribute to this growth.

For instance, as per the news on December 4, 2023, Countries eligible for Gavi support can request the introduction of diphtheria, tetanus, and pertussis (DPT) vaccine boosters, along with the option to transition to hexavalent vaccines. Hexavalent vaccines are six-in-one formulations that include the pentavalent vaccine (covering diphtheria, tetanus, and whole-cell pertussis.

Geography Analysis-

High Vaccination Coverage and Strategic Partnerships are the Key Factors Contributingto the Market Growth in the North American Region.

North America maintains high vaccination coverage rates, driven by comprehensive immunization programs and public health initiatives. This ensures a steady demand for DPT vaccines. Stringent regulatory frameworks and strong recommendations from health authorities, such as the CDC (Centers for Disease Control and Prevention) in the United States and Health Canada, play a crucial role in promoting DPT vaccination.

For instance, in April 2022, Ontario has expanded its publicly funded immunization program to include a routine Tdap (tetanus, diphtheria, pertussis) vaccine dose during every pregnancy. This expansion aims to protect against pertussis, commonly known as whooping cough. The National Advisory Committee on Immunization (NACI) has thoroughly reviewed the evidence supporting pertussis vaccination and recommends offering the Tdap vaccine to all pregnant individuals, irrespective of their previous Tdap vaccination history. This measure is intended to safeguard newborns from pertussis infection post-birth.

In addition, vaccine manufacturers collaborate with pharmaceutical firms to enhance research and development capabilities, optimize production processes, and expand distribution networks. These partnerships accelerate the introduction of new vaccines and ensure adequate supply to meet market demands.

For example, In June 2021, VAXELIS™, developed by Merck (NYSE: MRK) and Sanofi Pasteur, is the first and only hexavalent (six-in-one) pediatric combination vaccine available in the United States. It combines immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b. Approved for children aged 6 weeks to 4 years, VAXELIS™ aims to simplify vaccination schedules by reducing the number of shots needed according to CDC recommendations.

The Rising Prevalence of Diptheria in India and Research and Developments by Market Players are Expected to Generate a Larger Demand for Diphtheria, Pertussis, and Tetanus (DPT) Vaccines in Asia Pacific Region

India has witnessed a rising prevalence of diphtheria cases in recent years. This resurgence is partly due to gaps in vaccination coverage, particularly in rural and underserved areas. The resurgence poses a significant public health challenge, prompting urgent measures to control the spread of the disease.

For instance, as on September 5, 2023, the Ministry of Health in Guinea the Ministry of Health in Guinea notified the World Health Organization (WHO) about a significant diphtheria outbreak. The outbreak occurred between July 4 and October 13, 2023, with a total of 538 reported cases in the Kankan region. The high number of cases within a relatively short period underscores the severity of the outbreak and the urgent need for effective public health responses. Diphtheria can lead to severe complications and has a high mortality rate if not treated promptly. This situation underscores the ongoing need for strong immunization programs of DPT vaccine and healthcare systems to prevent such outbreaks and protect public health globally.

In addition, research and development by players also spurring market growth. Companies are investing in expanding their production capacities to meet the increasing demand for vaccines. This includes setting up new manufacturing facilities and upgrading existing ones.

For instance, on October 6, 2023, it was announced that the Serum Institute of India, India's most valuable unlisted company, is set to expand its presence into wealthier nations. This strategic move aims to broaden the company's global reach, leveraging its strong position in the vaccine industry to penetrate new, more affluent markets.

What you can gain from Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Report–

• Provides an in-depth analysis of the dynamics of the Diphtheria, Pertussis, and Tetanus (DPT) Vaccine segment across various regions.

• Diphtheria, Pertussis, and Tetanus (DPT) Vaccine research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country Level.
• Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine report covers extensive analysis of emerging trends and the competitive landscape.
• Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine report helps to identify opportunities in the marketplace.

Global Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Segmentation

By Type:

• Tetanus & Diphtheria (TD)
• Diphtheria-Tetanus-acellular-Pertussis (DTaP)
• Tetanus-Diphtheria-acellular-Pertussis (Tdap)

By Age Group:

• Pediatric
• Adult

By End-User:

• Clinics
• Hospitals
• Vaccination Centers

By Regional & Country Level:

• North America
  • S.
  • Canada
• Europe
  • K.
  • France
  • Germany
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Southeast Asia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa